home / stock / drmaw / drmaw quote
Last: | $0.0131 |
---|---|
Change Percent: | 0.76% |
Open: | $0.013 |
Close: | $0.0131 |
High: | $0.0131 |
Low: | $0.013 |
Volume: | 6,510 |
Last Trade Date Time: | 07/02/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$0.0131 | $0.013 | $0.0131 | $0.0131 | $0.013 | 6,510 | 07-02-2024 |
$0.014 | $0.012899 | $0.014 | $0.014 | $0.012899 | 2,175 | 06-28-2024 |
$0.013 | $0.00998 | $0.013 | $0.013 | $0.0082 | 6,100 | 06-27-2024 |
$0.0079 | $0.0079 | $0.0079 | $0.0079 | $0.0079 | 2,500 | 06-24-2024 |
$0.0079 | $0.008001 | $0.0079 | $0.013 | $0.0079 | 1,434 | 06-21-2024 |
$0.014 | $0.014 | $0.014 | $0.014 | $0.014 | 100 | 06-20-2024 |
$0.007 | $0.0159 | $0.007 | $0.0159 | $0.007 | 27,600 | 06-10-2024 |
$0.0082 | $0.008 | $0.0082 | $0.0082 | $0.008 | 2,200 | 06-07-2024 |
$0.0081 | $0.0081 | $0.0081 | $0.0081 | $0.0081 | 276 | 06-03-2024 |
$0.0081 | $0.0159 | $0.0081 | $0.0159 | $0.0081 | 1,101 | 05-31-2024 |
$0.0081 | $0.0081 | $0.0081 | $0.0081 | $0.0081 | 1,000 | 05-30-2024 |
$0.01 | $0.01 | $0.01 | $0.01 | $0.01 | 2,088 | 05-29-2024 |
$0.0107 | $0.0107 | $0.0107 | $0.0107 | $0.0107 | 130 | 05-28-2024 |
$0.0159 | $0.0159 | $0.0159 | $0.0159 | $0.0159 | 400 | 05-23-2024 |
$0.0107 | $0.0124 | $0.0107 | $0.0124 | $0.0107 | 1,628 | 05-22-2024 |
$0.0165 | $0.0169 | $0.0165 | $0.0169 | $0.0165 | 1,526 | 05-20-2024 |
$0.0169 | $0.0087 | $0.0169 | $0.017 | $0.0086 | 24,989 | 05-17-2024 |
$0.0085 | $0.0169 | $0.0085 | $0.0169 | $0.008 | 36,122 | 05-16-2024 |
$0.0169 | $0.0169 | $0.0169 | $0.0169 | $0.0169 | 1,100 | 05-13-2024 |
$0.0096 | $0.0096 | $0.0096 | $0.0096 | $0.0096 | 4,000 | 05-08-2024 |
News, Short Squeeze, Breakout and More Instantly...
Dermata Therapeutics Inc. Warrant Company Name:
DRMAW Stock Symbol:
NASDAQ Market:
Dermata Therapeutics Inc. Warrant Website:
SAN DIEGO, CA / ACCESSWIRE / May 17, 2024 / Dermata Therapeutics, Inc. (Nasdaq:DRMA)(Nasdaq:DRMAW) ("Dermata," or the "Company"), a late-stage biotechnology company focused on the treatment of medical and aesthetic skin diseases and conditions, today announced the entry into definitive agreement...
- DMT310 Phase 3 Spongilla Treatment of Acne Research (STAR-1) clinical trial enrollment remains on track - - Dermata continues discussions with potential botulinum toxin partners for DMT410 - - Received issuance of Japanese patent for DMT410 for the treatment of hyperhidrosis - SAN...
- This is the Company's first patent issued for DMT410, using its Spongilla technology to topically deliver botulinum toxin for hyperhidrosis - - The Company is currently discussing partnership opportunities to advance development of DMT410 - - In 2022, the Japanese prevalence of hyperhid...